Findings seen in combination with chemotherapy following surgery in patients with curative intent<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Oct. 21, 2024 (HealthDay News) — Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in the Journal of Clinical Oncology<\/em>.<\/p>\n Brian M. Slomovitz, M.D., from Mount Sinai Medical Center in Miami Beach, and colleagues conducted a protocol-prespecified subgroup analysis of patients with mismatch repair-deficient (dMMR) endometrial cancer from the phase 3 ENGOT-en11\/GOG-3053\/KEYNOTE-B21 study undergoing surgery with curative intent. The analysis included patients randomly assigned to pembrolizumab 200 mg or placebo (six cycles) plus carboplatin-paclitaxel (four to six cycles) every three weeks, then pembrolizumab 400 mg (141 patients) or placebo (140 patients) every six weeks (six cycles).<\/p>\n The researchers reported that an interim analysis showed DFS favored pembrolizumab (hazard ratio, 0.31), with median DFS not reached in either group. For pembrolizumab and placebo, two-year DFS rates were 92.4 and 80.2 percent, respectively. No new safety signals were reported. <\/p>\n “Preplanned subgroup analysis based on the study\u2019s stratification factors suggests that pembrolizumab plus chemotherapy improves DFS and is clinically relevant for patients with dMMR tumors in the curative-intent setting,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n